美泊利单抗在慢阻肺中的疗效:三项临床试验血嗜酸性粒细胞计数纵向模式及变异性分析
本研究汇总METREX、METREO和MATINEE三项3期随机双盲安慰剂对照试验数据,评估美泊利单抗100 mg在血嗜酸性粒细胞计数(BEC)不同纵向模式慢阻肺患者中的疗效。结果显示,在具有2型炎症特征(包括BEC持续升高或间歇升高)的患者中,美泊利单抗降低或趋向降低中重度急性加重年化率,并减少需急诊就诊和/或住院的急性加重;BEC持续低于150 cells/µL者无获益。
要点
- BEC任一随机化前时间点≥300 cells/µL者,美泊利单抗使中重度急性加重年化率降低21%。
- BEC持续升高者中重度急性加重降低12%–27%,BEC随时间波动者降低22%–36%。
- BEC持续低于150 cells/µL的患者未从美泊利单抗获益,识别可治疗嗜酸性表型无需BEC持续升高。
核心结论
- 美泊利单抗改善具有2型炎症特征的慢阻肺患者急性加重相关结局,该特征表现为BEC持续或间歇升高。
- 识别慢阻肺可治疗嗜酸性表型不要求BEC持续升高。
研究设计与样本
- 汇总三项3期随机双盲安慰剂对照试验METREX(NCT02105948)、METREO(NCT02105961)和MATINEE(NCT04133909)的数据。
- 纳入接受美泊利单抗100 mg或安慰剂的患者,所有患者均有随机化前12个月内历史BEC记录。
- 按随机化前12个月、筛查时和基线的BEC值划分亚组评估结局。
主要发现
- BEC在任一随机化前时间点≥300 cells/µL者,美泊利单抗组中重度急性加重年化率降低21%。
- BEC持续升高者中重度急性加重年化率降低12%–27%,BEC随时间波动者降低22%–36%。
- 在BEC升高(起始≥150 cells/µL)的各亚组中,美泊利单抗减少需急诊就诊和/或住院的急性加重。
- BEC持续低于150 cells/µL的患者未从美泊利单抗获益。
关键数值与推荐
- BEC≥300 cells/µL(任一随机化前时间点):中重度急性加重年化率降低21%。
- BEC持续升高:中重度急性加重年化率降低12%–27%;BEC随时间波动:降低22%–36%。
- BEC升高亚组从≥150 cells/µL起:美泊利单抗减少需急诊就诊和/或住院的急性加重。
- BEC持续<150 cells/µL:无获益。
临床怎么用
- 对慢阻肺患者可结合随机化前多个时间点BEC评估2型炎症,间歇性BEC升高者也可能从美泊利单抗获益。
- BEC持续低于150 cells/µL者不建议依据嗜酸性表型选择美泊利单抗。
- 关注美泊利单抗对需急诊就诊和/或住院的急性加重的减少作用。
局限性
- 本研究为三项随机对照试验数据的汇总分析,结果基于亚组评估。
- 原文未报告各亚组样本量、置信区间及P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Blood eosinophil count (BEC) is a biomarker indicating type 2 inflammation in patients with chronic obstructive pulmonary disease (COPD), but can be variable. OBJECTIVES: Evaluate mepolizumab efficacy in patients with COPD with variability of BEC patterns. METHODS: Data were pooled from the phase 3, randomized, double-blind, placebo-controlled METREX (NCT02105948), METREO (NCT02105961), and MATINEE (NCT04133909) trials. Patients receiving mepolizumab 100 mg or placebo were included. These trials documented historical BEC (within 12 months before randomization) for all patients. Outcomes included annualized rates of moderate or severe exacerbations, and exacerbations requiring an emergency department (ED) visit and/or hospitalization. Outcomes were assessed in subgroups based on BEC values in the 12 months before randomization, at screening, and at baseline. MEASUREMENTS AND MAIN RESULTS: Annualized rates of moderate or severe exacerbations were reduced, or trended toward reduction, with mepolizumab versus placebo in patients with type 2 inflammation characteristics, including those with BEC ≥300 cells/µL at any pre-randomization timepoint (21% reduction), persistently elevated BECs (12%-27% reduction), and -variable BECs over time (22%-36% reduction). Across various subgroups with elevated BEC, starting from ≥150 cells/µL, mepolizumab reduced exacerbations requiring ED visit and/or hospitalization. Patients with persistently low BEC (<150 cells/µL) experienced no benefit with mepolizumab. CONCLUSIONS: Mepolizumab improved exacerbation-related outcomes in patients with COPD and type 2 inflammation, characterized by both consistently and intermittently elevated BEC. Persistent BEC elevation is not required to identify treatable eosinophilic phenotypes in COPD.
引用
- Criner, Watz, Han, et al. Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials. Am J Respir Crit Care Med. 2026. PMID: 42265988. doi:10.1093/ajrccm/aamag288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。